Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3406]

Applying the syndemic framework to cancer research for effective cancer control...

Dr Zahid Butt - University of Waterloo, Waterloo, Canada

Applying the syndemic framework to cancer research for effective cancer control in LMICs ( Dr Zahid Butt - University of Waterloo, Waterloo, Canada )

Cetuximab with XELOX or XELIRI is tolerable and effective in RAS wild-type mCRC

Dr Jamal Zekri - King Faisal Specialist Hospital & Research Centre, Riyadh...

Cetuximab with XELOX or XELIRI is tolerable and effective in RAS wild-type mCRC ( Dr Jamal Zekri - King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia )

Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity...

Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain

Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity for patients with nonsquamous NSCLC ( Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain )

Pegargiminase-pemetrexed-platinum triplet therapy prolongs survival in non...

Prof Peter Szlosarek - Barts Cancer Institute, London, UK

Pegargiminase-pemetrexed-platinum triplet therapy prolongs survival in non-epithelioid pleural mesothelioma ( Prof Peter Szlosarek - Barts Cancer Institute, London, UK )

CheckMate 649 biomarker analyses of NIVO + IPI vs chemo for patients with GC...

Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA

CheckMate 649 biomarker analyses of NIVO + IPI vs chemo for patients with GC/GEJC/EAC ( Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA )

Initial results from a phase 1 dose escalation trial of E-602 shows efficacy in...

Dr Jason Luke - University of Pittsburgh, Pittsburgh, USA

Initial results from a phase 1 dose escalation trial of E-602 shows efficacy in solid tumours ( Dr Jason Luke - University of Pittsburgh, Pittsburgh, USA )

Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant...

Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA

Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours ( Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA )

Durable effect of imatinib and metronomic chemotherapy with capecitabine in...

Dr Sana Al-Sukhun - Al Hyatt Oncology Practice, Amman, Jordan

Durable effect of imatinib and metronomic chemotherapy with capecitabine in pancreatic carcinoma ( Dr Sana Al-Sukhun - Al Hyatt Oncology Practice, Amman, Jordan )

IO-108 shows promising results in the treatment of advanced relapsed or...

Dr Matthew Taylor - Providence Cancer Institute, Portland, USA

$IO-108 shows promising results in the treatment of advanced relapsed or refractory solid tumours ( Dr Matthew Taylor - Providence Cancer Institute, Portland, USA )$

The role of CDK4/6 inhibitors in the treatment of metastatic breast cancer

Dr Delia Guaqueta - Memorial Healthcare System, Miami, USA

The role of CDK4/6 inhibitors in the treatment of metastatic breast cancer ( Dr Delia Guaqueta - Memorial Healthcare System, Miami, USA )

Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR...

Prof Nicolas Girard - Institut Curie, Paris, France

Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC ( Prof Nicolas Girard - Institut Curie, Paris, France )

Four chemo cycles given with durvalumab and tremelimumab optimise response and...

Dr Niels Reinmuth - University of Muenster, Gauting, Germany

Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC ( Dr Niels Reinmuth - University of Muenster, Gauting, Germany )

More from ecancer